FIGURE 5 from Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors
Year: 2023
Type: other
Abstract: Effects of KRB-456 on cell viability, levels of KRAS bound to GTP, binding of KRAS to RAF1, and the levels of P-MEK and P-ERK in human pancreatic cancer cells that harbor KRAS G12D. Human pancreatic cancer cell lines Panc0203 and Panc1 were treated with the indicated concentrations of KRB-456 and processed for viability assays (72 hours), Panc0203 (open circles) and Panc1 (closed circles; A), GST-RBD pulldown (“G” designates GST-RBD only with no lysate added; B), immuno-precipitation with RAS antibody and blotting with RAF1 and KRAS antibodies (C), and Panc0203 and Panc01 cells were treated with 0, 1, 3, and 10 µmol/L KRB-456 for 2 hours and processed for Western blotting as described in Materials and Methods (D).
Authors: Aslamuzzaman Kazi, Alok Ranjan, Vasantha Kumar M.V., Bogos Agianian, Martin Garcia Chavez, Vignesh Vudatha, Rui Wang, Rajanikanth Vangipurapu, Liwei Chen, Perry Kennedy, Karthikeyan Subramanian, Jonathan C.K. Quirke, Francisca Beato, Patrick W. Underwood, Jason B. Fleming, Jose Trevino, Paul J. Hergenrother, Evripidis Gavathiotis, Said M. Sebti
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4390347692